Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma

被引：39
|
作者：
Fragioudaki, M. [1 ]
Tsirakis, G. [1 ]
Pappa, C. A. [2 ]
Aristeidou, I. [1 ]
Tsioutis, C. [1 ]
Alegakis, A. [3 ]
Kyriakou, D. S. [4 ]
Stathopoulos, E. N. [5 ]
Alexandrakis, M. G. [1 ]
机构：
[1] Univ Hosp Heraklion, Dept Hematol, Iraklion 71110, Crete, Greece
[2] Venizel Hosp Heraklion, Dept Hematol, Iraklion, Greece
[3] Univ Crete, Sch Med, Iraklion, Greece
[4] Univ Hosp Larisa, Blood Bank, Larisa, Greece
[5] Univ Hosp Heraklion, Dept Pathol, Iraklion 71110, Crete, Greece
来源：
LEUKEMIA RESEARCH | 2012年 / 36卷 / 08期
关键词：
Multiple myeloma; Angiogenesis; Cytokines; BAFF; Prognosis; BONE-MARROW ANGIOGENESIS; B-LYMPHOCYTE STIMULATOR; MALIGNANT PLASMA-CELLS; NECROSIS-FACTOR FAMILY; NF-KAPPA-B; STAGING SYSTEM; MICROVESSEL DENSITY; CLINICAL-FEATURES; ACTIVATING FACTOR; HODGKIN-LYMPHOMA;
D O I：
10.1016/j.leukres.2012.03.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B-cell activating factor (BAFF) is a B-cell growth factor. We measured its serum levels and correlated them with parameters of disease activity, as serum levels of tumor necrosis factor-alpha and lactate dehydrogenase, bone marrow microvascular density and proliferating cell nuclear antigen expression, in 50 myeloma patients, in 22 of them in plateau phase and in 20 controls. All of them were higher in patients and in advanced disease while reduced in plateau phase. BAFF correlated with all the above markers. Higher BAFF levels predicted a shorter survival, suggesting an important prognostic marker and a possible therapeutic target in myeloma. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1004 / 1008
页数：5
相关论文
共 50 条
  • [21] Serum Hepcidin Levels in Multiple Myeloma
    Victor, Manolov
    Evgeniy, Hadjiev
    Gergana, Tzvetkova
    Julia, Petrova
    Vasil, Vasilev
    Borislav, Marinov
    Ivo, Bogov
    Zlatina, Gramatikova
    Kamen, Tzatchev
    CLINICAL LABORATORY, 2017, 63 (7-8) : 1273 - 1277
  • [22] The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma
    Scudla, V.
    Pika, T.
    Budikova, M.
    Petrova, J.
    Minarik, J.
    Bacovsky, J.
    Langova, K.
    Zivna, J.
    NEOPLASMA, 2010, 57 (02) : 102 - 110
  • [23] Parathyroid hormone levels and prognosis in multiple myeloma?
    Vassiliou, George
    Tung, Joanna Su Ling
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 154 - 155
  • [24] Serum BAFF and APRIL levels in patients with alopecia areata
    Kuwano, Yoshihiro
    Fujimoto, Manabu
    Watanabe, Rei
    Ishiura, Nobuko
    Nakashima, Hiroko
    Ohno, Yuki
    Yano, Shoichiro
    Yazawa, Norihito
    Okochi, Hitoshi
    Tamaki, Kunihiko
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2008, 50 (03) : 236 - 239
  • [25] Elevated serum BAFF levels in patients with autoimmune hepatitis
    Migita, Kiyoshi
    Abiru, Seigo
    Maeda, Yumi
    Nakamura, Minoru
    Komori, Atsumasa
    Ito, Masahiro
    Fujiwara, Shinsuke
    Yano, Koji
    Yatsuhashi, Hiroshi
    Eguchi, Katsumi
    Ishibashi, Hiromi
    HUMAN IMMUNOLOGY, 2007, 68 (07) : 586 - 591
  • [26] Elevated Serum BAFF Levels in Patients with Autoimmunity and Lymphoproliferation
    Janda, A.
    Rensing-Ehl, A.
    Eibel, H.
    Ehl, S.
    Speckmann, C.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2011, 74 (05) : 518 - 519
  • [27] Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma
    Wei, Yujun
    Wang, Jinying
    Chen, Fei
    Li, Xin
    Zhang, Jiajia
    Shen, Man
    Tang, Ran
    Huang, Zhongxia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma
    Haraguchi, Kouichi
    Uto, Hirofumi
    Ohnou, Nobuhito
    Tokunaga, Masahito
    Tokunaga, Mayumi
    Utsunomiya, Atae
    Hanada, Shuichi
    Tsubouchi, Hirohito
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (04) : 581 - 588
  • [29] INTERLEUKIN-6 SERUM LEVELS IN PATIENTS WITH MULTIPLE-MYELOMA
    EMILE, C
    FERMAND, JP
    DANON, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (02) : 439 - 440
  • [30] Serum BLYS and Soluble (sBCMA) Levels in Multiple Myeloma (MM) Patients
    Gkioka, Annita-Ioanna
    Alexandropoulos, Alexandros
    Gkiokas, Alexandros
    Papadatou-Gigante, Mavra
    Koudouna, Aspasia
    Tryfou, Thommais-Marina
    Bartzi, Vasiliki
    Kyrtsonis, Marie-Christine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S136 - S136
12345